#Nasdaq Play $RGC : CEO Figuratively Putting His M
Post# of 103032
NASDAQ:RGC
Investors have faced challenging and volatile markets so far in 2022 as they sort through issues of inflation, supply chain disruption, continued covid issues, rising interest rates, and the disruption of the war in Ukraine. The S&P 500 has come close to bear market levels, down 19% in mid-June.
Times of turbulence affect all stocks, large and small. It can be particularly challenging for pre-revenue microcap stocks, where the volatility is often magnified by small changes in perception, whether driven by news or technical trading signals.
We first wrote on Regencell Bioscience (NASDAQ:RGC) and its preliminary trials for ASD/ADHD, in November 2021. At that time, the stock was trading around $20/share. It rose to $40 by mid-February 2022, before dropping back to the low 20s in early April.
https://finance.yahoo.com/news/rgc-ceo-figura...00965.html